How much of Thermo Electron's 1997 earnings came from accounting gains rather than operations?

The company recorded $80.1 million of nontaxable gains from subsidiaries issuing stock, which is roughly a third of the $239.3 million net income. Net income was also reduced by $74.4 million of minority interest expense. Investors should separate recurring operating earnings from these gains, which depend on market conditions and are not guaranteed to recur, as the filing itself warns.

What drove the revenue growth in 1997?

Acquisitions were the main driver. Instruments revenue rose $383 million (32%), with Thermo Instrument acquisitions adding $407 million. Biomedical Products grew 29% and Industrial Outsourcing 12%. Organic growth was more modest, and currency translation reduced revenue by about $47 million in Instruments alone.

How leveraged is the company and what is the debt structure?

Long-term obligations were $1.74 billion at year-end 1997, with convertible obligations of about $1.66 billion at carrying value. Much of this debt is issued by subsidiaries and convertible into their stock, and is guaranteed by the parent in most cases on a subordinated basis. A January 1998 $250 million convertible issue by Thermo Instrument added to this. Shareholders' investment was $2.0 billion, so debt is significant relative to equity.

What are the most significant legal and operating risks disclosed?

The filing discloses a Fischer Imaging patent suit against Trex Medical's prone breast-biopsy systems (cumulative product revenue about $118.6 million), an arbitration by former Epsilon employees seeking $27-46 million plus punitive damages, and a False Claims Act qui tam suit against Thermo Coleman. Thermo Ecotek faces risk from its Gillette, Wyoming coal-beneficiation plant, which has operational problems, and from possible PSNH bankruptcy affecting its New Hampshire plants. Management says it does not expect the litigation to be material to financial position, but adverse outcomes could affect quarterly or annual results.

TMO 10-K FY1998 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K/A filed April 3, 1998. Cited figures are marked; the original filing is the authoritative source.

This filing is Amendment No. 1 on Form 10-K/A from Thermo Electron Corporation (NYSE: TMO) for the fiscal year ended January 3, 1998, filed April 3, 1998.

The amendment largely restates the business description and attaches the 1997 Annual Report (Exhibit 13) containing audited financials. Thermo Electron is a diversified technology holding company that operates through majority-owned public and private subsidiaries across six segments: Instruments, Alternative-energy Systems, Paper Recycling, Biomedical Products, Industrial Outsourcing, and Advanced Technologies. Its spinout model has produced substantial value, but it also creates a dependence on the subsidiaries' capital markets activity.

Reported 1997 revenue rose 21% to $3,558.3 million^a, and operating income rose 65% to $405.8 million. Net income increased 25% to $239.3 million, or $1.41 diluted EPS. Investors should note that net income includes $80.1 million of nontaxable gains on stock issuances by subsidiaries, down from $126.6 million in 1996.

Much of the earnings quality therefore depends on the timing of subsidiary equity transactions, a risk management itself flags. Instruments drove most of the growth through acquisitions, including Life Sciences International and Fisons. The balance sheet expanded materially, with total assets up to $5.8 billion^b and goodwill up 56% to $1.69 billion, driven by acquisitions.

Convertible debt rose to roughly $1.66 billion^c carrying value, and minority interest reached $719.6 million. Consolidated cash and investments were $1.59 billion, of which $1.33 billion sat in majority-owned subsidiaries. Management also flagged several legal and operational risks, including the Fischer patent suit, the Bruker/Finnigan ITC matter, a Thermo Ecotek Gillette plant that is still struggling operationally, and New Hampshire utility deregulation exposure at Thermo Ecotek.

02—Key points

Key Highlights

Revenue grew 21% to $3,558.3 million in 1997 (from $2,932.6 million), with Instruments up 32% largely from acquisitions.
Operating income rose 65% to $405.8 million, though net income benefited from $80.1 million of nontaxable subsidiary stock-issuance gains (down from $126.6 million in 1996).
Diluted EPS was $1.41 versus $1.17 in 1996; basic EPS was $1.57 versus $1.35.
Total assets reached $5.80 billion, with goodwill of $1.69 billion (up from $1.08 billion), reflecting heavy acquisition activity including Life Sciences International ($442.8 million net).
Long-term obligations rose to $1.74 billion, and minority interest to $719.6 million; $1.33 billion of the $1.59 billion in cash and investments is held by majority-owned subsidiaries.
Key risks disclosed include litigation (Fischer patent suit against Trex Medical, Finnigan/Bruker ITC matter, an Epsilon arbitration claiming $27-46 million), the unresolved Gillette coal-beneficiation plant operating issues, and PSNH bankruptcy exposure for Thermo Ecotek's New Hampshire plants.
The company has never paid cash dividends and has 28 subsidiaries that have sold minority equity stakes (23 publicly traded), a structure central to its growth strategy and capital-raising model.

03—Questions

Frequently Asked Questions

How much of Thermo Electron's 1997 earnings came from accounting gains rather than operations?
The company recorded $80.1 million of nontaxable gains from subsidiaries issuing stock, which is roughly a third of the $239.3 million net income. Net income was also reduced by $74.4 million of minority interest expense. Investors should separate recurring operating earnings from these gains, which depend on market conditions and are not guaranteed to recur, as the filing itself warns.
What drove the revenue growth in 1997?
Acquisitions were the main driver. Instruments revenue rose $383 million (32%), with Thermo Instrument acquisitions adding $407 million. Biomedical Products grew 29% and Industrial Outsourcing 12%. Organic growth was more modest, and currency translation reduced revenue by about $47 million in Instruments alone.
How leveraged is the company and what is the debt structure?
Long-term obligations were $1.74 billion at year-end 1997, with convertible obligations of about $1.66 billion at carrying value. Much of this debt is issued by subsidiaries and convertible into their stock, and is guaranteed by the parent in most cases on a subordinated basis. A January 1998 $250 million convertible issue by Thermo Instrument added to this. Shareholders' investment was $2.0 billion, so debt is significant relative to equity.
What are the most significant legal and operating risks disclosed?
The filing discloses a Fischer Imaging patent suit against Trex Medical's prone breast-biopsy systems (cumulative product revenue about $118.6 million), an arbitration by former Epsilon employees seeking $27-46 million plus punitive damages, and a False Claims Act qui tam suit against Thermo Coleman. Thermo Ecotek faces risk from its Gillette, Wyoming coal-beneficiation plant, which has operational problems, and from possible PSNH bankruptcy affecting its New Hampshire plants. Management says it does not expect the litigation to be material to financial position, but adverse outcomes could affect quarterly or annual results.

04—Continue

← View all 10-K filings